Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Replimune Group, Inc. - Common Stock (NQ:REPL)

15.63 +0.39 (+2.56%)
Streaming Delayed Price Updated: 12:11 PM EDT, Aug 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,277,133
Open 15.00
Bid (Size) 15.63 (300)
Ask (Size) 15.68 (3,900)
Prev. Close 15.24
Today's Range 14.98 - 15.65
52wk Range 1.500 - 15.68
Shares Outstanding 46,772,263
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL
From Pomerantz LLP
Via GlobeNewswire

Performance

YTD
+75.6%
+75.6%
1 Month
+57.3%
+57.3%
3 Month
+194.9%
+194.9%
6 Month
+101.4%
+101.4%
1 Year
+197.7%
+197.7%

More News

Read More
News headline image
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law
From Schall, Brown & Schwartz LLP
Via GlobeNewswire
News headline image
REPL INVESTOR ALERT: Securities Class Action Filed Against Replimune Group, Inc. – Investors Encouraged to Contact Kirby McInerney LLP
From Kirby McInerney LLP
Via Business Wire
News headline image
REPLIMUNE CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Replimune Group Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Replimune Announces Pricing of $150 Million Underwritten Offering
From Replimune, Inc.
Via GlobeNewswire
News headline image
Replimune Group, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – REPL
From DJS Law Group
Via Business Wire
News headline image
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
Deadline Soon: Replimune Group, Inc. (REPL) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Deadline Approaching: Replimune Group, Inc. (REPL) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Deadline Alert: Replimune Group, Inc. (REPL) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
Law Offices of Howard G. Smith Encourages Replimune Group, Inc. (REPL) Shareholders to Inquire About Securities Fraud Class Action
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Law Offices of Frank R. Cruz Encourages Replimune Group, Inc. (REPL) Shareholders To Inquire About Securities Fraud Class Action
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Stockholder Alert: Robbins LLP Informs Investors of the Replimune Group, Inc. Class Action
From Robbins LLP
Via Business Wire
News headline image
REPL CLASS ACTION NOTICE: Glancy Prongay Wolke & Rotter LLP Files Securities Fraud Lawsuit On Behalf Of Replimune Group, Inc. Investors
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen
From Replimune, Inc.
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. is Investigating Replimune Group Inc. on Behalf of Replimune Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
REPL SHAREHOLDER ALERT: Replimune Group Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
From Kirby McInerney LLP
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
From Pomerantz LLP
Via GlobeNewswire
Top movers in Friday's session ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Via Benzinga
Top stock movements in today's session. ↗
Via Chartmill
Gapping stocks in Friday's session ↗
Via Chartmill
Friday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Via Benzinga

Frequently Asked Questions

Is Replimune Group, Inc. - Common Stock publicly traded?
Yes, Replimune Group, Inc. - Common Stock is publicly traded.
What exchange does Replimune Group, Inc. - Common Stock trade on?
Replimune Group, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Replimune Group, Inc. - Common Stock?
The ticker symbol for Replimune Group, Inc. - Common Stock is REPL on the Nasdaq Stock Market
What is the current price of Replimune Group, Inc. - Common Stock?
The current price of Replimune Group, Inc. - Common Stock is 15.63
When was Replimune Group, Inc. - Common Stock last traded?
The last trade of Replimune Group, Inc. - Common Stock was at 08/13/26 12:11 PM ET
What is the market capitalization of Replimune Group, Inc. - Common Stock?
The market capitalization of Replimune Group, Inc. - Common Stock is 731.07M
How many shares of Replimune Group, Inc. - Common Stock are outstanding?
Replimune Group, Inc. - Common Stock has 731M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.